The rise of Sildenafil initially sparked a boom for the drug industry, but recent changes present a complicated scenario for shareholders. Lower-cost competitors are reducing earnings, and continued litigation add more https://robertxywb135766.dailyhitblog.com/46820784/the-blue-pill-and-big-pharma-a-volatile-investment